{"id":"W4410799986","doi":"10.1016/s2352-3026(25)00051-1","title":"Beyond maximum grade: tolerability of immunotherapies, cellular therapies, and targeted agents in haematological malignancies","year":2025,"lang":"en","type":"review","venue":"The Lancet Haematology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"National Cancer Institute; Astellas Pharma; Swedish Orphan Biovitrum; Else Kröner-Fresenius-Stiftung; Incyte; BeiGene; Eli Lilly and Company; AstraZeneca; Arnold Ventures; Adaptive Biotechnologies; Gilead Sciences; Sanofi; Amgen; National Heart, Lung, and Blood Institute; Pfizer; Seagen; Cidara Therapeutics; National Institute of Allergy and Infectious Diseases; Celgene; GlaxoSmithKline","keywords":"Medicine; Tolerability; Oncology; Immunotherapy; Internal medicine; Intensive care medicine; Adverse effect; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008595796,0.0006246498,0.002610556,0.001286407,0.0001930572,0.002132928,0.001178303,0.001281235,0.002222523],"category_scores_gemma":[0.007673155,0.0002351583,0.001421994,0.001303545,0.001003406,0.002592752,0.0009537793,0.002790364,0.0005696003],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001261892,"about_ca_system_score_gemma":0.001538522,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008936938,"about_ca_topic_score_gemma":0.001391488,"domain_scores_codex":[0.9964511,0.00157334,0.0006996217,0.0002183492,0.0009483719,0.000109149],"domain_scores_gemma":[0.9925802,0.00474507,0.001421989,0.0001842035,0.0009435239,0.0001249615],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0003229744,0.0000488925,0.0003373264,0.02643078,0.00029476,0.0001122721,0.0001536756,0.0005229376,0.001615471,0.006237314,0.01005199,0.9538715],"study_design_scores_gemma":[0.0002881814,0.002006077,0.005567438,0.03394414,0.00140992,0.002849424,0.0004824132,0.0006129393,0.004179861,0.01569951,0.9328183,0.0001418406],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0003676447,0.9972351,0.0003724267,0.0009365592,0.0001721093,0.000016199,0.00002518607,0.000007623032,0.0008672455],"genre_scores_gemma":[0.01262969,0.983061,0.0009531847,0.001623316,0.0007872501,0.00005460189,0.00008019156,0.00001022815,0.0008005761],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.008595796,"threshold_uncertainty_score":0.04545945,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09745188310624656,"score_gpt":0.3748129590262169,"score_spread":0.2773610759199703,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}